FY2024 EPS Estimates for TransMedics Group, Inc. Lifted by William Blair (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) – William Blair increased their FY2024 earnings estimates for shares of TransMedics Group in a report released on Wednesday, July 31st. William Blair analyst R. Daniels now anticipates that the company will post earnings of $0.52 per share for the year, up from their previous estimate of $0.28. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.30 EPS and FY2025 earnings at $0.67 EPS.

Several other equities analysts have also weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Morgan Stanley lifted their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Piper Sandler boosted their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $166.88.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $156.10 on Monday. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of -459.12 and a beta of 1.99. The firm’s fifty day simple moving average is $144.18 and its 200 day simple moving average is $111.99. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $171.98.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Mackenzie Financial Corp bought a new stake in TransMedics Group in the 4th quarter valued at $35,804,000. Wasatch Advisors LP bought a new position in TransMedics Group during the 1st quarter valued at about $32,162,000. First Turn Management LLC bought a new position in TransMedics Group during the 4th quarter valued at about $25,509,000. Vaughan Nelson Investment Management L.P. bought a new position in TransMedics Group during the 2nd quarter valued at about $39,862,000. Finally, First Light Asset Management LLC lifted its holdings in TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $129.82, for a total value of $324,550.00. Following the completion of the sale, the director now directly owns 11,193 shares of the company’s stock, valued at approximately $1,453,075.26. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Stephen Gordon sold 20,000 shares of the stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $141.40, for a total transaction of $2,828,000.00. Following the transaction, the chief financial officer now owns 21,299 shares in the company, valued at approximately $3,011,678.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David Weill sold 2,500 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the transaction, the director now owns 11,193 shares in the company, valued at approximately $1,453,075.26. The disclosure for this sale can be found here. In the last three months, insiders sold 48,921 shares of company stock valued at $6,934,803. Company insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.